Get the Stockscreener App
4.03
1.71%
-0.07
After Hours:
4.08
0.05
+1.24%
Curis Inc stock is traded at $4.03, with a volume of 107.98K.
It is down -1.71% in the last 24 hours and down -26.06% over the past month.
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
See More
Previous Close:
$4.10
Open:
$4.09
24h Volume:
107.98K
Relative Volume:
1.84
Market Cap:
$34.12M
Revenue:
$10.16M
Net Income/Loss:
$-47.57M
P/E Ratio:
-0.4319
EPS:
-9.33
Net Cash Flow:
$-42.73M
1W Performance:
+2.03%
1M Performance:
-26.06%
6M Performance:
-62.75%
1Y Performance:
-51.91%
1-Day Range:
$3.81
$4.2124
1-Week Range:
$3.60
$4.2124
52-Week Range:
$3.51
$17.49
Curis Inc Stock (CRIS) Company Profile
Name
Curis Inc
Sector
Industry
Phone
617-503-6500
Address
128 SPRING STREET, LEXINGTON, MA
Compare CRIS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| CRIS | 4.03 | 34.12M | 10.16M | -47.57M | -42.73M | -9.33 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Curis Inc Stock (CRIS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-04-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-13-21 | Initiated | Raymond James | Outperform |
| Mar-25-21 | Initiated | B. Riley Securities | Buy |
| Jul-29-20 | Initiated | Laidlaw | Buy |
| Jul-17-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Mar-02-16 | Initiated | Sun Trust Rbsn Humphrey | Buy |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Aug-11-15 | Initiated | FBR Capital | Outperform |
| Jan-22-15 | Reiterated | Oppenheimer | Outperform |
| Jan-21-15 | Reiterated | ROTH Capital | Buy |
| May-09-14 | Reiterated | Oppenheimer | Outperform |
| Oct-02-13 | Initiated | Robert W. Baird | Outperform |
| Sep-30-13 | Initiated | Chardan Capital Markets | Buy |
| Nov-14-12 | Initiated | Stifel Nicolaus | Hold |
| Jan-31-12 | Reiterated | Brean Murray | Buy |
| Jan-31-12 | Reiterated | Summer Street Research | Buy |
| Dec-09-11 | Initiated | Oppenheimer | Outperform |
| Oct-06-11 | Initiated | Summer Street Research | Buy |
| Sep-22-11 | Initiated | MLV Capital | Buy |
| Mar-21-11 | Reiterated | Brean Murray | Buy |
| Feb-26-10 | Reiterated | Roth Capital | Buy |
| Jan-07-10 | Initiated | Roth Capital | Buy |
View All
Curis Inc Stock (CRIS) Latest News
Curis to Report Third Quarter 2024 Financial and Operating Resul - GuruFocus.com
Curis Provides Third Quarter 2024 Business Update - GuruFocus.com
Curis: Q3 Earnings Snapshot - Marketscreener.com
Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Curis’ (CRIS) Buy Rating Reiterated at HC Wainwright - Defense World
Curis Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Curis, Inc. (NASDAQ:CRIS) Q3 2024 Earnings Call Transcript - Insider Monkey
Curis Inc (CRIS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ... - Yahoo Finance
Curis Inc (CRIS) Q3 2024 Earnings Call Highlights: Navigating Fi - GuruFocus.com
Curis Inc. Reports Positive Q3 2024 Earnings - TipRanks
Curis reports progress in clinical trials By Investing.com - Investing.com Australia
Curis Inc (CRIS) Quarterly 10-Q Report - Quartzy
Curis Inc (CRIS) Q3 2024 Earnings: Revenue Surpasses Estimates a - GuruFocus.com
Curis reports progress in clinical trials - Investing.com
Curis Reports Improved Q3 Loss, Achieves Strong Clinical Response in Cancer Study | CRIS Stock News - StockTitan
Curis, Inc.'s (NASDAQ:CRIS) 26% Dip In Price Shows Sentiment Is Matching Revenues - Simply Wall St
Curis (FRA:CUS0) Total Inventories : €0.00 Mil (As of Jun. 2024) - GuruFocus.com
Kingdon Capital Management Reduces Stake in Curis Inc - GuruFocus.com
Curis stock touches 52-week low at $3.95 amid market challenges - Investing.com India
Curis Inc (CRIS) Q3 2024: Everything You Need to Know Ahead of E - GuruFocus.com
Curis (CRIS) Set to Announce Quarterly Earnings on Thursday - Defense World
Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024 - BioSpace
Curis (CRIS) to Report Q3 2024 Earnings: Key Updates on IRAK4 Inhibitor Progress | CRIS Stock News - StockTitan
Curis Inc. (CRIS) Stock Surges 5.08% Amid Strong Biotech Sector Performance - GuruFocus.com
Curis stock hits 52-week low at $4.05 amid market challenges - Investing.com Canada
Curis shares remain Buy-rated, H.C. Wainwright lowers target after cash infusion extends runway - Investing.com Canada
500: Something went wrong - Investing.com
Curis price target lowered to $20 from $26 at H.C. Wainwright - Yahoo Finance
Curis (CRIS) Stock Plummets Over 5% Amid Lack of Institutional R - GuruFocus.com
Curis to Report Second Quarter 2024 Financial and Operating Resu - GuruFocus.com
Curis looks to raise $12.1M in private placement - MSN
Curis Announces $12.1 Million Registered Direct and Concurrent Private Placement - citybiz
When the Price of (CRIS) Talks, People Listen - Stock Traders Daily
Data Readouts At EHA Congress 2021 (APTO, XFOR, GBT, CRIS…) - RTTNews
(CRIS) On The My Stocks Page - Stock Traders Daily
Combs Hit With Slew Of Assault Suits Dating Back To 1995 - Law360
Histone Deacetylase 3 Industry Size Share Growth Trends and Forecast Analysis (2024-2034) - La Funcion mx
Curis (CRIS) Stock Surges Over 6% Amid Biotechnology Sector Gains - GuruFocus.com
Curis Inc (CRIS) Q2 2024 Earnings Call Highlights: Promising Clinical Progress Amid Financial ... - Yahoo Finance
Trend Tracker for (CRIS) - Stock Traders Daily
Elutia (NASDAQ:ELUT) vs. Curis (NASDAQ:CRIS) Head to Head Comparison - Defense World
Curis shares hold Buy rating on symposium insights By Investing.com - Investing.com South Africa
Curis shares hold Buy rating on symposium insights - Investing.com India
Curis Inc Stock (CRIS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
2.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):